Dr. Ruchika Goel is the inaugural recipient of the O.H. Wesly Endowed Chair of Excellence in Hematologic Disorders. The investiture ceremony on August 26 honored both Goel’s remarkable career as a physician-scientist and the enduring legacy of Dr. Wesly, whose generosity made the endowment possible.

At SIU School of Medicine, the story of hypertension research doesn’t begin in a distant lab. It begins in the clinic, often with a patient who has run out of options. A provider reviews the numbers. Despite multiple medications, lifestyle changes and follow-up visits, blood pressure remains stubbornly high. In that moment, a different path forward is offered: enrollment in a clinical trial conducted by SIU’s Hypertension Clinic. These trials are not theoretical with no practical outcome. They are active, evidence-based and available right here in central and southern Illinois. One of SIU’s

At SIU School of Medicine, the story of hypertension research doesn’t begin in a distant lab. It begins in the clinic, often with a patient who has run out of options. A provider reviews the numbers. Despite multiple medications, lifestyle changes and follow-up visits, blood pressure remains stubbornly high. In that moment, a different path forward is offered: enrollment in a clinical trial conducted by SIU’s Hypertension Clinic. These trials are not theoretical with no practical outcome. They are active, evidence-based and available right here in central and southern Illinois. One of SIU’s

At SIU School of Medicine, the story of hypertension research doesn’t begin in a distant lab. It begins in the clinic, often with a patient who has run out of options. A provider reviews the numbers. Despite multiple medications, lifestyle changes and follow-up visits, blood pressure remains stubbornly high. In that moment, a different path forward is offered: enrollment in a clinical trial conducted by SIU’s Hypertension Clinic. These trials are not theoretical with no practical outcome. They are active, evidence-based and available right here in central and southern Illinois. One of SIU’s

At SIU School of Medicine, the story of hypertension research doesn’t begin in a distant lab. It begins in the clinic, often with a patient who has run out of options. A provider reviews the numbers. Despite multiple medications, lifestyle changes and follow-up visits, blood pressure remains stubbornly high. In that moment, a different path forward is offered: enrollment in a clinical trial conducted by SIU’s Hypertension Clinic. These trials are not theoretical with no practical outcome. They are active, evidence-based and available right here in central and southern Illinois. One of SIU’s

At SIU School of Medicine, the story of hypertension research doesn’t begin in a distant lab. It begins in the clinic, often with a patient who has run out of options. A provider reviews the numbers. Despite multiple medications, lifestyle changes and follow-up visits, blood pressure remains stubbornly high. In that moment, a different path forward is offered: enrollment in a clinical trial conducted by SIU’s Hypertension Clinic. These trials are not theoretical with no practical outcome. They are active, evidence-based and available right here in central and southern Illinois. One of SIU’s

Research study will explore possible link with cytokine profiles, differences between men and women The Smith Alzheimer’s Center and Simmons Cancer Institute are teaming up to better understand the common side effect of “chemobrain,” and why some patients are at higher risk of developing it than others. Aida Adlimoghaddam, PhD of the Smith Alzheimer’s Center and Krishna Rao, MD of Simmons Cancer Institute received the Team Science Grant to explore the cytokine profiles (proteins that send signals throughout the body) that could contribute to variations in susceptibility to inflammation and

Research study will explore possible link with cytokine profiles, differences between men and women The Smith Alzheimer’s Center and Simmons Cancer Institute are teaming up to better understand the common side effect of “chemobrain,” and why some patients are at higher risk of developing it than others. Aida Adlimoghaddam, PhD of the Smith Alzheimer’s Center and Krishna Rao, MD of Simmons Cancer Institute received the Team Science Grant to explore the cytokine profiles (proteins that send signals throughout the body) that could contribute to variations in susceptibility to inflammation and